Pluristem Therapeutics will set up manufacturing sites and find local partners to make cell therapies for the Chinese, Korean, Mexican, Russian and Israeli markets after securing various patents this week.
The adoption of new technologies related to single-use bioreactors, disposable plastic containers, continuous purification processing, and real-time quality analysis are driving the next generation of biomanufacturing, according to a new report from the...
Innovate UK has awarded Crescendo Biologics a grant to fund development of drugs combining cytotoxic small molecule payloads with antibody fragments known as Humabodies.
Biomay has licensed a yeast-based expression system from fellow Austrian biotech VTU Technologies to use for the commercial production of its recombinant allergens.
Big Pharma is not the only slow moving behemoth involved in the CRISPR/Cas9 revolution with a US team citing the gene editing tech as key to its efforts to resurrect the woolly mammoth.
Medicago has ploughed $245m into an influenza vaccine plant that will use a tobacco-based technology it says produces high yields quicker than with egg-based platforms.
With the release of three final guidance documents on biosimilars, the FDA is offering more clarity for developers seeking to fine-tune their understanding of the science and quality of biosimilars.
A new round of €8.4m ($8.9m) in grants will help develop a scalable manufacturing process to wean vaccines off of their cold-chain dependency and help ensure they can be manufactured as stable and temperature independent.
San Antonio, Texas-based StemBioSys has closed an $8m round of Series A preferred stock financing that it will use to help launch its bone marrow-High Performance MicroEnvironment (BM-HPME) stem cell culture system.
Sartorius has launched a cell harvesting technology, the first to incorporate diatomaceous earth filtration more commonly associated with the brewing industry.
Bristol-Myers Squibb will use uniQure’s insect-cell based technology and manufacturing facilities to develop gene therapies for cardiovascular diseases in a deal potentially worth $2bn (€1.8bn).
Fujifilm will buy Cellular Dynamics International (CDI) for $307m to add induced stem cells to its offering and further build in regenerative medicines.
Sourcing human beta cells may soon no longer be a challenge for AstraZeneca diabetes researchers thanks to a new partnership with stem cell scientists at Harvard University.
Gene-editing technology CRISPR-Cas9 must not be used to alter human DNA until the risks have been researched and the ethical issues considered, say scientists.
Chinese cancer drug developer BeiGene will create production cell lines using a platform developed by Sigma Aldrich's custom manufacturing services business.
Ancient nomadic kings’ love of life in the saddle did not hamper another of their favourite pastimes according to a study suggesting millions of Asian men are descended from just 11 fathers.
The US FDA has delayed an advisory committee review of Celltrion's Remicade (infliximab) biosimilar after asking the South Korean drugmaker for more information.
Apotex’s Neupogen (filgrastim) copycat Grastofil could be on US pharmacy shelves as early as December, after the US Food and Drug Administration (FDA) started its review this week.
Australian stem cell and regenerative medicine company Cynata Therapeutics is now set to scale up manufacturing of its mesenchymal stem cells (MSCs) for therapeutic use.
Celltrion has emphasised the savings Remsima ((inflizimab) could offer at a conference in Spain as partner Napp Pharmaceuticals prepares to extend the roll out of the Remicade biosimilar to the UK.
Having shorter hair stops you becoming fat…at least it does if you are a stem cell say researchers who claim restricting the growth of hair-like cilia found on such cells could yield new treatments for obesity.
Boehringer-Ingelheim has renewed its collaboration with VTU technology to develop a yeast-based protein expression system for biopharmaceutical production.
Sanofi will invest in biologics and vaccine manufacturing capacity in 2015 to sustain product launches and ease constraints that impacted its Sanofi Pasteur division in the past few years.
Bankrupt cell therapy firm Dendreon has attracted more suitors according to stalking horse bidder Valeant, which upped its offer for the Provenge (sipuleucel-T) developer to $400m this week.
UPDATE: Merck says switching cell lines would impact safety and quality
The anti-abortion group that blames Merck & Co for the recent US measles outbreak says it would not judge parents who have children vaccinated with MMR II for the good of society.
US government scientists told a House subcommittee on oversight and investigations on Tuesday that the six months production time necessary for flu vaccine manufacturers can create difficulties for health experts selecting the appropriate virus strains...
Researchers have used shear stress to repair misfolded proteins in an approach that could help biopharmaceutical firms bypass expensive refolding techniques and time-consuming cell line optimization.
Abenza subsidiary Antitope has extended its relationship and will provide manufacturing cell lines for two developing HIV vaccines from the French National Institute of Health and Medical Research (INSERM); the National Health Agency for Research on AIDS...
Lonza signed a flurry of biopharma-related deals and launched a number of drug industry services in the final quarter of 2014 as its efforts to focus on pharma intensified.
Horizon says its £6m (€7.7m) purchase of Austrian biotech Haplogen Genomics means it can produce cell lines ten times faster than before using a haploid gene platform.
In a reversal from three years ago, the Court of Justice of the European Union (CJEU) ruled on Thursday that an organism incapable of developing into a human being is not a human embryo and may be patented.
